The biotech industry takes advantage of the new trend of accurate medical care to protect the country and mountains.

The biotech industry takes advantage of the new trend of accurate medical care to protect the country and mountains.

(Taiwan TB News Network / reporter Chen Mingzong) combined with advanced biotech industry policy receiving forum held on the 28th, the meeting looked at policy docking from an industrial perspective, hoping to further consider the most promising way of public-private partnership through cross-border exchanges, so as to accelerate the implementation and promotion of industrial policies, achieve the goal of rapid development of Taiwan's biomedical industry, and blow up the east wind of vigorous development of Taiwan's biotechnology industry.

Biotech industry is a key industry in national economic development. Coupled with the outbreak of COVID-19 's epidemic in 2020 and the efforts made by countries around the world to prevent and fight against epidemic, biotech medicine has become one of President Cai's six core strategic industries. The Executive Yuan formulates policy directions and puts forward overall recommendations through the Biotechnology Industry Strategy Advisory Committee (BTC) meeting every year. This year's BTC meeting ended smoothly on September 1st and triggered a number of strategic opinions that are very close to the industry in response to the COVID-19 epidemic.

With the support and leadership of the Ministry of Economic Affairs, the Biotechnology Development Center of the consortium has cultivated industrial technology for many years, has a cooperative network relationship with the industry, and is most familiar with the industrialization path from the industry. Soon after the BTC meeting, the biotechnology industry policy proposal was proposed and corresponding practices were actively put forward in order to facilitate the implementation of the policy. Together with the Taiwan Biological Industry Development Association and the Republic of China Development Pharmaceutical Research Association, we held a biotechnology industry policy receiving forum, hoping that the industry would take the initiative to accurately catch the ball and respond quickly to industrial policies.

The forum invites Yang Panchi, vice president of the National Biotechnology and Medical Industry Promotion Association, Zhang Hongren, chairman of Shangteng Technology, Chen Huajian, CEO of Action Gene, Chen Kangwei, president of AstraZeneca, Chen Chuncheng, chief medical officer of Guoguang Biotechnology, Liu Licheng, general manager of Taikang Biotechnology, Zeng Huijin, honorary deputy director of Zicheng, and Li Yizhen, general manager of Amgen Taiwan, to participate in the forum, focusing on how to implement precision medical / regenerative medical / digital medical industry. And create innovative biological manufacturing CDMO industry and other specific action thinking, in-depth and extensive discussion.

Tu Xingzhe, chairman of the Biotechnology Center, said that in his 2020 inaugural speech, President Cai declared to create "six core strategic industries", especially to include the biotechnology industry into the country's key development strategy industries, and the new draft amendment to the regulations on new biotech drugs simultaneously incorporated CDMO into the scope of tax concessions for the first time, demonstrating his determination to fully develop the biotechnology industry.

Wu Zhongxun, chief executive officer of the Biotechnology Center, pointed out that the BTC meeting has continued to put forward overall recommendations on talents, funds, regulations and international links for many years. Under the impact of the COVID-19 epidemic, the conclusions of the meeting put forward strategic suggestions for the development of vaccine and drug CDMO. The Biotechnology Center is a corporate body supported by the long-term science college plan of the Ministry of Economic Affairs. It is expected that the suggestions of experts and scholars from all walks of life can be fully integrated through this forum. Concatenated resources use public-private partnership (PPP) to lay the foundation for infrastructure, optimize the development environment of biotech industry, accelerate the digital transformation of biomedicine in Taiwan, and fully integrate with the new challenges of the post-epidemic era.

At present, the Biotechnology Center puts forward four major suggestions after the BTC meeting to develop various implementation strategies respectively. In terms of improving the ecosystem, the Biotechnology Center emphasizes the cultivation and recruitment of cross-disciplinary talents at home and abroad. The Biotechnology Center can integrate the talent training plans and resources of various ministries and committees, and establish a platform for cultivating key talents in Taiwan's biomedical industry.

In the construction of a healthy big data platform, we cooperate with-promote the new application of intelligent medical supervision sandboxie, and the Biotechnology Center focuses on big data's application of auxiliary drug development. a team has been established and has the ability to mine international biomedical databases, database cleaning and value-added, bioinformation operations. The integration of energy can help the industry develop data application products (such as SaMD) and accelerate the efficiency and success rate of drug development. To promote the public-private partnership of the big data platform, the Biotechnology Center has both research and business development capabilities, is familiar with domestic learning and research resources, and has experience in negotiation and cooperation with large international manufacturers, which can help China's health big data platform to dock with the international market. accelerate the development of digital health industry.

For the deployment of innovative biological manufacturing CDMO industry, with past experience in mass production and plant construction of biotech drugs, the Biotechnology Center has quickly invested in the establishment of long-chain mRNA production, LNP coating technology, tissue targeted delivery system and insect cell production technology, as well as the development of nucleic acid drugs and key processes. Echoing committee member BTC, he mentioned that the decisive points for the establishment of vaccine and emerging pharmaceutical CDMO are 4S: science (Science), speed (Speed), scope (Scope) and scale (Scale). The Biotechnology Center quickly counts the capacity of China's protein drugs and vaccine commercial mass production plants, works out a plan for a nucleic acid drug CDMO plant with a capacity of 1 billion doses, actively links domestic industries, and strives for strategic input support. I hope to replicate once again the successful experience of Taikang Biotechnology derived from the Biotechnology Center.

Tu Xingzhe, chairman of the Biotechnology Center (third from right), Yang Panchi, Vice President of the National Biotechnology and Medical Industry Promotion Association (second from right), and Wu Zhongxun, CEO of Biotechnology Center (first from right)